OR WAIT null SECS
Under the terms of the partnership, Colorcon will work to accelerate i2O’s research and development efforts.
Colorcon announced on Dec. 3, 2020 that it is entering into a research collaboration with i2O Therapeutics, a US-based biotechnology company, to aid in the development of i2O’s liquid technology for the oral delivery of challenging drugs.
Under the terms of the partnership, Colorcon will work to accelerate the company’s research and development efforts, a Colorcon press release said.
“We are excited to collaborate with Colorcon to help advance our ionic liquid technology given their rich history of innovation and expertise in pharmaceutical development,” said Samir Mitragotri, PhD, co-founder of i2O Therapeutics, in the press release.
“Colorcon Ventures’ strategic focus on technologies that transform conventional delivery pathways aligns well with i2O,” added Martti Hedman, Colorcon’s CEO, in the press release. “The ability to deliver injectable therapies orally has the potential to significantly improve patient adherence and outcomes.”